Common cholesterol drug may shield myeloma patients from chemo nerve pain
NCT ID NCT07025005
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether fenofibrate, a drug typically used for high cholesterol, can prevent or reduce nerve damage caused by a common chemotherapy regimen for multiple myeloma. The trial will enroll 44 newly diagnosed patients, half receiving fenofibrate alongside their standard treatment and half receiving standard treatment alone. Researchers will measure nerve damage through questionnaires and blood tests over six treatment cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fenofibrate
What this could lead to
If it works, fenofibrate could become a simple, low-cost way to prevent painful nerve damage in multiple myeloma patients undergoing chemotherapy.
What could go wrong
This is a small, early-phase study with only 44 participants. The results may not apply to all patients, and fenofibrate may not reduce nerve damage as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL NEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Damanhur Oncology Center
RECRUITINGDamanhur, El- Behira, Egypt
-
Tanta University
RECRUITINGTanta, El-Gharbya, Egypt